The FDA granted accelerated approval to AstraZeneca’s oral SERD camizestrant (Etcamah) for first-line use in a defined breast cancer population, according to the report. The decision came after an advisory committee vote in April had opposed approval. The approval is tied to ESR1 mutation status and was accompanied by a Guardant Health companion diagnostic test. Analysts framed the decision as enabling an earlier treatment switch than standard-of-care approaches that require progression before switching.